LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 12, 2016--
Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of therapies for ocular diseases, today announced
that Carsten Boess has been appointed to its Board of Directors and the
Audit Committee of Inotek’s Board.
“Carsten brings a wealth of global management and finance experience to
our Board,” commented David P. Southwell, President and Chief Executive
Officer of Inotek. “We are particularly fortunate to have his financial
and business acumen as we build Inotek’s ophthalmology franchise.”
Mr. Boess is the Chief Business Officer at Kiniksa Pharmaceuticals, a
privately held biotechnology company. He previously served as Senior
Vice President and Chief Financial Officer at Synageva Biopharma
Corporation from 2011 until the company’s acquisition by Alexion
Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served
in multiple roles with increasing responsibility for Insulet
Corporation, including Chief Financial Officer from 2006 to 2009 and
Vice President of International Operations from 2009 to 2011. Prior to
that, Mr. Boess served as Executive Vice President of Finance for Serono
Inc. from 2005 to 2006. In addition, he was a member of the Geneva based
World Wide Executive Finance Management Team while involved with Serono.
Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals,
and was a finance executive at Novozymes of North America and Novo
Nordisk in France, Switzerland and China.
“With their first-in-class therapy, trabodenoson, currently in Phase 3
development for glaucoma and ocular hypertension, this truly is an
exciting time to join the Inotek team,” commented Mr. Boess. “I look
forward to contributing to the development of Inotek’s strategic vision
and long range plans as we look to 2016 and beyond.”
About Inotek Pharmaceuticals Corporation
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek's laboratories
and designed to restore the eye's natural pressure control mechanism.
Additionally, the Company is evaluating the potential for selective
adenosine mimetics to address optic neuropathies and other degenerative
retinal diseases. For more information, please visit www.inotekpharma.com.
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. These forward-looking statements often
include words such as "believe," "expect," "anticipate," "intend,"
"plan," "estimate," "seek," "will," "may" or similar expressions.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160112005435/en/
Source: Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals Corporation
Claudine Prowse, Ph.D.,
Vice President, Strategy and Investor Relations Officer
MacDougall Biomedical Communications